Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.37 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.37 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.37 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.37 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.37 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.37 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.37 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.36 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17646055 | 1.00 | HTR6 (0.40) | HTR6CHRM2CHRM1POLBCYP2C9 | |
| SCHEMBL17659101 | 0.93 | HTR6 (0.45) | HTR6POLBMAPTRXFP1ATP1A1 | |
| SCHEMBL17681316 | 0.89 | LRRK2 (0.37) | HTR6CYP2C9NAMPTATP1A1ATP1B1 | |
| SCHEMBL17659098 | 0.88 | CNR2 (0.41) | NAMPTMAPTALDH1A1CNR2 | |
| SCHEMBL17659149 | 0.86 | ALDH1A1 (0.36) | HTR6POLBMAPTRXFP1ATP1A1 | |
| SCHEMBL17659105 | 0.83 | OPRD1 (0.41) | POLBALDH1A1 | |
| SCHEMBL17659107 | 0.83 | OPRD1 (0.41) | POLBALDH1A1 | |
| SCHEMBL17659087 | 0.82 | EGFR (0.36) | HTR6NAMPTALDH1A1 | |
| SCHEMBL17659106 | 0.82 | ALDH1A1 (0.34) | HTR6POLBMAPTRXFP1ATP1A1 | |
| SCHEMBL17659097 | 0.78 | CYP2D6 (0.38) | NAMPTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204007-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1 INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| EP-3204007-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Flatley Discovery Lab, LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | CFTR, KCNJ11, KCNJ1 | HTR6 3059/4885CHRM2 333/4885CHRM1 677/4885 |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | HTR6 3059/4885CHRM2 333/4885CHRM1 677/4885 |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | HTR6 3059/4885CHRM2 333/4885CHRM1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.